Myasthenia Gravis Market Dynamics and Analysis by 2031
The Myasthenia Gravis Market is expected to register a CAGR of 10.3% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The Myasthenia Gravis Market report covers analysis By Treatment (Drug treatment, Rapid immunotherapies), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Myasthenia Gravis Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Myasthenia Gravis Market Segmentation
Treatment- Drug treatment
- Rapid immunotherapies
Strategic Insights
Myasthenia Gravis Market Growth Drivers- Increasing Prevalence of Myasthenia Gravis (MG):
The rising incidence of Myasthenia Gravis, an autoimmune neuromuscular disorder, is a significant driver of the market. As awareness and diagnosis improve, more cases of MG are being identified, leading to a growing patient population in need of treatment and care options.
- Advancements in Treatment Options:
Recent developments in the understanding of Myasthenia Gravis have led to more targeted and effective therapies. The introduction of newer biologics and monoclonal antibodies, along with advancements in immunosuppressive therapies, is expanding the treatment landscape and improving patient outcomes.
- Rising Demand for Personalized Medicine:
The trend toward personalized or precision medicine is gaining traction in the MG market. This approach tailors treatments based on individual patient profiles, improving efficacy and minimizing side effects.
- Increased Use of Thymectomy:
Thymectomy, the surgical removal of the thymus gland, is increasingly being used as a treatment option for patients with generalized Myasthenia Gravis, particularly in those with thymoma. Studies continue to highlight the long-term benefits of thymectomy, contributing to its growing use in combination with other treatments.
- Shift Toward Combination Therapies:
There is a growing trend towards the use of combination therapies in the treatment of Myasthenia Gravis. Combining immunosuppressive drugs, biologics, and other treatments allows for a more comprehensive approach to managing the disease, offering better disease control and improved patient outcomes.
- Growing Focus on Improving Diagnosis and Early Detection:
The development of more advanced diagnostic techniques, such as antibody testing and electrophysiological assessments, is allowing for earlier and more accurate diagnosis of Myasthenia Gravis.
- Emerging Markets:
As the health care infrastructure improves in emerging markets, the opportunities for Myasthenia Gravis treatments are enormous. There is an untapped market with a growing patient base in these regions, such as parts of Asia-Pacific and Latin America, for effective MG therapies. - Advancements in Gene Therapy:
The development of gene therapy can prove promising in the treatment of Myasthenia Gravis. Gene therapies would directly target the genetic and molecular causes of the disease and could provide long-term, even curative solutions, for MG. Thus, further research and clinical trials in gene therapy create huge opportunities for innovation in the market.
- Increase in Patient Support Services and Community Involvement:
An increased MG patient population allows expansion opportunities in the area of counseling, physical therapy, and other support groups. Further opportunity to expand the market includes community engagement and specialized services for enhancing the quality of life of MG patients.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Myasthenia Gravis Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Myasthenia Gravis Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORKHave a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Myasthenia Gravis Market is estimated to witness a CAGR of 10.3% from 2023 to 2031.
The major factors driving the market are: Advancements in biologics and immunotherapies, Growing awareness and diagnostic rates, Rising prevalence of autoimmune disorders
Key future trends in this market are -
Key companies of this market are: Novartis AG, NIHON PHARMACEUTICAL CO., LTD, Grifols, S.A., Bausch Health, Alexion, F. Hoffmann-La Roche Ltd, Curavac, Bristol-Myers Squibb Company, Ra Pharmaceuticals, Inc, argenx,
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Myasthenia Gravis Market - By Treatment
1.3.2 Myasthenia Gravis Market - By Region
1.3.2.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. MYASTHENIA GRAVIS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. MYASTHENIA GRAVIS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. MYASTHENIA GRAVIS MARKET - GLOBAL MARKET ANALYSIS
6.1. MYASTHENIA GRAVIS - GLOBAL MARKET OVERVIEW
6.2. MYASTHENIA GRAVIS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. MYASTHENIA GRAVIS MARKET - REVENUE AND FORECASTS TO 2028 - TREATMENT
7.1. OVERVIEW
7.2. TREATMENT MARKET FORECASTS AND ANALYSIS
7.3. DRUG TREATMENT
7.3.1. Overview
7.3.2. Drug treatment Market Forecast and Analysis
7.3.3. Cholinesterase Inhibitors Market
7.3.3.1. Overview
7.3.3.2. Cholinesterase Inhibitors Market Forecast and Analysis
7.3.4. Monoclonal Antibodies Market
7.3.4.1. Overview
7.3.4.2. Monoclonal Antibodies Market Forecast and Analysis
7.3.5. Chronic Immunomodulators. Market
7.3.5.1. Overview
7.3.5.2. Chronic Immunomodulators. Market Forecast and Analysis
7.4. RAPID IMMUNOTHERAPIES
7.4.1. Overview
7.4.2. Rapid immunotherapies Market Forecast and Analysis
7.4.3. Plasmapheresis Market
7.4.3.1. Overview
7.4.3.2. Plasmapheresis Market Forecast and Analysis
7.4.4. Intravenous Immunoglobulin (IVlg) Market
7.4.4.1. Overview
7.4.4.2. Intravenous Immunoglobulin (IVlg) Market Forecast and Analysis
7.4.5. Thymectomy Market
7.4.5.1. Overview
7.4.5.2. Thymectomy Market Forecast and Analysis
8. MYASTHENIA GRAVIS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1 North America Myasthenia Gravis Market Overview
8.1.2 North America Myasthenia Gravis Market Forecasts and Analysis
8.1.3 North America Myasthenia Gravis Market Forecasts and Analysis - By Treatment
8.1.4 North America Myasthenia Gravis Market Forecasts and Analysis - By Countries
8.1.4.1 United States Myasthenia Gravis Market
8.1.4.1.1 United States Myasthenia Gravis Market by Treatment
8.1.4.2 Canada Myasthenia Gravis Market
8.1.4.2.1 Canada Myasthenia Gravis Market by Treatment
8.1.4.3 Mexico Myasthenia Gravis Market
8.1.4.3.1 Mexico Myasthenia Gravis Market by Treatment
8.2. EUROPE
8.2.1 Europe Myasthenia Gravis Market Overview
8.2.2 Europe Myasthenia Gravis Market Forecasts and Analysis
8.2.3 Europe Myasthenia Gravis Market Forecasts and Analysis - By Treatment
8.2.4 Europe Myasthenia Gravis Market Forecasts and Analysis - By Countries
8.2.4.1 Germany Myasthenia Gravis Market
8.2.4.1.1 Germany Myasthenia Gravis Market by Treatment
8.2.4.2 France Myasthenia Gravis Market
8.2.4.2.1 France Myasthenia Gravis Market by Treatment
8.2.4.3 Italy Myasthenia Gravis Market
8.2.4.3.1 Italy Myasthenia Gravis Market by Treatment
8.2.4.4 Spain Myasthenia Gravis Market
8.2.4.4.1 Spain Myasthenia Gravis Market by Treatment
8.2.4.5 United Kingdom Myasthenia Gravis Market
8.2.4.5.1 United Kingdom Myasthenia Gravis Market by Treatment
8.3. ASIA-PACIFIC
8.3.1 Asia-Pacific Myasthenia Gravis Market Overview
8.3.2 Asia-Pacific Myasthenia Gravis Market Forecasts and Analysis
8.3.3 Asia-Pacific Myasthenia Gravis Market Forecasts and Analysis - By Treatment
8.3.4 Asia-Pacific Myasthenia Gravis Market Forecasts and Analysis - By Countries
8.3.4.1 Australia Myasthenia Gravis Market
8.3.4.1.1 Australia Myasthenia Gravis Market by Treatment
8.3.4.2 China Myasthenia Gravis Market
8.3.4.2.1 China Myasthenia Gravis Market by Treatment
8.3.4.3 India Myasthenia Gravis Market
8.3.4.3.1 India Myasthenia Gravis Market by Treatment
8.3.4.4 Japan Myasthenia Gravis Market
8.3.4.4.1 Japan Myasthenia Gravis Market by Treatment
8.3.4.5 South Korea Myasthenia Gravis Market
8.3.4.5.1 South Korea Myasthenia Gravis Market by Treatment
8.4. MIDDLE EAST AND AFRICA
8.4.1 Middle East and Africa Myasthenia Gravis Market Overview
8.4.2 Middle East and Africa Myasthenia Gravis Market Forecasts and Analysis
8.4.3 Middle East and Africa Myasthenia Gravis Market Forecasts and Analysis - By Treatment
8.4.4 Middle East and Africa Myasthenia Gravis Market Forecasts and Analysis - By Countries
8.4.4.1 South Africa Myasthenia Gravis Market
8.4.4.1.1 South Africa Myasthenia Gravis Market by Treatment
8.4.4.2 Saudi Arabia Myasthenia Gravis Market
8.4.4.2.1 Saudi Arabia Myasthenia Gravis Market by Treatment
8.4.4.3 U.A.E Myasthenia Gravis Market
8.4.4.3.1 U.A.E Myasthenia Gravis Market by Treatment
8.5. SOUTH AND CENTRAL AMERICA
8.5.1 South and Central America Myasthenia Gravis Market Overview
8.5.2 South and Central America Myasthenia Gravis Market Forecasts and Analysis
8.5.3 South and Central America Myasthenia Gravis Market Forecasts and Analysis - By Treatment
8.5.4 South and Central America Myasthenia Gravis Market Forecasts and Analysis - By Countries
8.5.4.1 Brazil Myasthenia Gravis Market
8.5.4.1.1 Brazil Myasthenia Gravis Market by Treatment
8.5.4.2 Argentina Myasthenia Gravis Market
8.5.4.2.1 Argentina Myasthenia Gravis Market by Treatment
9. INDUSTRY LANDSCAPE
9.1. MERGERS AND ACQUISITIONS
9.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
9.3. NEW PRODUCT LAUNCHES
9.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
10. MYASTHENIA GRAVIS MARKET, KEY COMPANY PROFILES
10.1. NOVARTIS AG
10.1.1. Key Facts
10.1.2. Business Description
10.1.3. Products and Services
10.1.4. Financial Overview
10.1.5. SWOT Analysis
10.1.6. Key Developments
10.2. NIHON PHARMACEUTICAL CO., LTD
10.2.1. Key Facts
10.2.2. Business Description
10.2.3. Products and Services
10.2.4. Financial Overview
10.2.5. SWOT Analysis
10.2.6. Key Developments
10.3. GRIFOLS, S.A
10.3.1. Key Facts
10.3.2. Business Description
10.3.3. Products and Services
10.3.4. Financial Overview
10.3.5. SWOT Analysis
10.3.6. Key Developments
10.4. BAUSCH HEALTH
10.4.1. Key Facts
10.4.2. Business Description
10.4.3. Products and Services
10.4.4. Financial Overview
10.4.5. SWOT Analysis
10.4.6. Key Developments
10.5. ALEXION
10.5.1. Key Facts
10.5.2. Business Description
10.5.3. Products and Services
10.5.4. Financial Overview
10.5.5. SWOT Analysis
10.5.6. Key Developments
10.6. F. HOFFMANN-LA ROCHE LTD
10.6.1. Key Facts
10.6.2. Business Description
10.6.3. Products and Services
10.6.4. Financial Overview
10.6.5. SWOT Analysis
10.6.6. Key Developments
10.7. CURAVAC
10.7.1. Key Facts
10.7.2. Business Description
10.7.3. Products and Services
10.7.4. Financial Overview
10.7.5. SWOT Analysis
10.7.6. Key Developments
10.8. BRISTOL-MYERS SQUIBB COMPANY
10.8.1. Key Facts
10.8.2. Business Description
10.8.3. Products and Services
10.8.4. Financial Overview
10.8.5. SWOT Analysis
10.8.6. Key Developments
10.9. RA PHARMACEUTICALS, INC
10.9.1. Key Facts
10.9.2. Business Description
10.9.3. Products and Services
10.9.4. Financial Overview
10.9.5. SWOT Analysis
10.9.6. Key Developments
10.10. ARGENX
10.10.1. Key Facts
10.10.2. Business Description
10.10.3. Products and Services
10.10.4. Financial Overview
10.10.5. SWOT Analysis
10.10.6. Key Developments
11. APPENDIX
11.1. ABOUT THE INSIGHT PARTNERS
11.2. GLOSSARY OF TERMS
- Novartis AG
- NIHON PHARMACEUTICAL CO. , LTD
- Grifols, S. A.
- Bausch Health
- Alexion
- F. Hoffmann-La Roche Ltd
- Curavac
- Bristol-Myers Squibb Company
- Ra Pharmaceuticals, Inc
- argenx
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.